当前位置:首页 - 行情中心 - 欧康医药(920230) - 财务分析 - 现金流量表

欧康医药

(920230)

  

流通市值:5.22亿  总市值:11.10亿
流通股本:4724.78万   总股本:1.00亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金169,314,010.4892,294,208.24342,454,164.74259,115,711.46
  收到的税费返还3,115,039.581,434,782.527,289,050.713,799,165.51
  收到其他与经营活动有关的现金1,802,9201,188,329.584,766,582.284,225,521.1
  经营活动现金流入小计174,231,970.0694,917,320.34354,509,797.73267,140,398.07
  购买商品、接受劳务支付的现金134,356,003.5257,185,313.94299,155,453.38235,045,144.04
  支付给职工以及为职工支付的现金13,638,285.797,859,130.0822,986,026.2815,288,466.22
  支付的各项税费2,597,626.491,035,435.254,822,4203,416,280.1
  支付其他与经营活动有关的现金2,263,491.051,357,482.7320,547,010.779,908,693.07
  经营活动现金流出小计152,855,406.8567,437,362347,510,910.43263,658,583.43
  经营活动产生的现金流量净额21,376,563.2127,479,958.346,998,887.33,481,814.64
二、投资活动产生的现金流量:
  收回投资收到的现金152,999,398.6211,183,657186,734,488.8289,174,936.82
  取得投资收益收到的现金93,592.358,303.85944,990.9418,875.9
  处置固定资产、无形资产和其他长期资产收回的现金净额50,112.8117,851.08130,567117,476.5
  收到的其他与投资活动有关的现金---20,000
  投资活动现金流入小计153,143,103.7811,209,811.93187,810,046.7289,731,289.22
  购建固定资产、无形资产和其他长期资产支付的现金6,401,051.845,769,708.0627,370,17017,826,320.08
  投资支付的现金137,760,00030,190,000177,806,91582,336,915
  投资活动现金流出小计144,161,051.8435,959,708.06205,177,085100,163,235.08
  投资活动产生的现金流量净额8,982,051.94-24,749,896.13-17,367,038.28-10,431,945.86
三、筹资活动产生的现金流量:
  吸收投资收到的现金--1,101,6001,101,600
  取得借款收到的现金15,000,0001,000,00021,000,00011,000,000
  收到其他与筹资活动有关的现金--102,986.8-
  筹资活动现金流入小计15,000,0001,000,00022,204,586.812,101,600
  偿还债务支付的现金16,036,761.11-20,000,00010,000,000
  分配股利、利润或偿付利息支付的现金15,345,801.39143,472.228,352,460.548,201,956.36
  支付其他与筹资活动有关的现金1,177,742.12-549,135.46262,577.17
  筹资活动现金流出小计32,560,304.62143,472.2228,901,59618,464,533.53
  筹资活动产生的现金流量净额-17,560,304.62856,527.78-6,697,009.2-6,362,933.53
四、汇率变动对现金及现金等价物的影响-200,042.48-269,724.71-115,822.79-51,143.59
五、现金及现金等价物净增加额12,598,268.053,316,865.28-17,180,982.97-13,364,208.34
  加:期初现金及现金等价物余额5,630,407.735,630,407.7322,811,390.722,811,390.7
  期末现金及现金等价物余额18,228,675.788,947,273.015,630,407.739,447,182.36
补充资料:
  净利润5,498,112.52-11,435,251.17-
  资产减值准备29,039.8-3,791,435.11-
  固定资产和投资性房地产折旧11,186,939.69-20,430,537.62-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧11,186,939.69-20,430,537.62-
  无形资产摊销351,307.56-639,557-
  处置固定资产、无形资产和其他长期资产的损失21,588.97-975,561.19-
  公允价值变动损失-8,741.87--32,327.74-
  财务费用305,301.51-776,951.73-
  投资损失-373,858.28--526,165.91-
  递延所得税3,064.48-78,684.84-
  其中:递延所得税资产减少16,692.71-78,684.84-
    递延所得税负债增加-13,628.23---
  存货的减少-7,215,585.57--10,226,179.99-
  经营性应收项目的减少15,840,359.43--23,369,924.78-
  经营性应付项目的增加-5,681,645.49--3,365,765.85-
  其他1,898,602.01-5,349,153.08-
  不涉及现金收支的投资和筹资活动金额其他项目186,742.76-390,402.54-
  现金的期末余额18,228,675.78-5,630,407.73-
  减:现金的期初余额5,630,407.73-22,811,390.7-
  现金及现金等价物的净增加额12,598,268.05--17,180,982.97-
公告日期2026-08-272026-04-292026-04-152025-10-30
审计意见(境内)标准无保留意见
TOP↑